Can I Take Lion's Mane with MOTS-c?

What MOTS-c and Lion's Mane Actually Do

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA. It was first characterized in 2015 by Lee et al. At the University of Southern California, who demonstrated that it activates the AMPK-AICAR pathway, shifting cellular metabolism toward glucose uptake and fatty acid oxidation [1]. Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom whose bioactive compounds, hericenones and erinacines, stimulate nerve growth factor (NGF) synthesis in vitro and in animal models [2].

How MOTS-c Works at the Cellular Level

MOTS-c enters the nucleus in response to metabolic stress and regulates gene expression tied to the antioxidant response element (ARE) pathway. A 2016 study in Cell Metabolism showed that MOTS-c administration improved insulin sensitivity and reduced diet-induced obesity in mice at a dose of 5 mg/kg intraperitoneally over 7 days [1]. The peptide does not undergo hepatic cytochrome P450 metabolism. It is a short peptide cleared renally, which means it shares no metabolic enzymes with orally ingested compounds like lion's mane.

How Lion's Mane Works

Erinacines cross the blood-brain barrier and promote NGF release in the hippocampus. A double-blind, placebo-controlled trial by Mori et al. (2009) gave 30 Japanese adults aged 50 to 80 with mild cognitive impairment 250 mg tablets of lion's mane three times daily for 16 weeks. Cognitive function scores on the Revised Hasegawa Dementia Scale improved significantly (p=0.032) compared to placebo [2]. Lion's mane is metabolized through standard gastrointestinal absorption and hepatic processing, primarily by phase II conjugation enzymes (glucuronidation and sulfation) rather than CYP450 isoforms [3].

Why a Pharmacokinetic Interaction Is Unlikely

A pharmacokinetic interaction happens when one substance changes how another is absorbed, distributed, metabolized, or eliminated. MOTS-c and lion's mane have almost no pharmacokinetic overlap.

Different Absorption Routes

MOTS-c is administered subcutaneously in research settings. It enters the bloodstream directly, bypassing gastrointestinal absorption entirely. Lion's mane is taken orally. The two compounds never compete for intestinal transport proteins or gastric pH-dependent absorption.

No Shared Metabolic Enzymes

MOTS-c, as a short mitochondrial-derived peptide, is degraded by peptidases and cleared through the kidneys. It does not interact with cytochrome P450 enzymes [1]. Lion's mane polysaccharides and terpenoids are processed through phase II conjugation. An in vitro study using human liver microsomes found no significant inhibition of CYP1A2, CYP2C9, CYP2D6, or CYP3A4 by Hericium erinaceus extracts at concentrations up to 100 mcg/mL [3]. Without shared enzymatic pathways, one compound cannot raise or lower the blood levels of the other.

Protein Binding Is Not a Concern

MOTS-c has low plasma protein binding due to its small size and hydrophilic amino acid composition. Lion's mane bioactives are similarly not highly protein-bound. Competition for albumin binding sites, which drives many clinically significant drug interactions, does not apply here.

The Pharmacodynamic Question: Where Overlap Exists

A pharmacodynamic interaction occurs when two substances produce additive or opposing effects on the same biological system, even without changing each other's blood levels. This is where MOTS-c and lion's mane deserve closer attention.

AMPK and Neuroprotection: Parallel but Not Conflicting Pathways

MOTS-c activates AMPK, which among its many downstream effects enhances mitochondrial biogenesis and reduces oxidative stress [1]. Lion's mane has shown neuroprotective effects partly through reducing oxidative damage in neuronal cells. A 2020 study in the International Journal of Molecular Sciences found that Hericium erinaceus mycelium enriched with erinacine A reduced amyloid plaque burden in APP/PS1 transgenic mice and lowered hippocampal oxidative stress markers by 28% over 30 days [4]. These pathways run in parallel. Both reduce oxidative stress through different upstream triggers. No published evidence suggests they antagonize each other.

The Platelet Aggregation Consideration

This is the one area of theoretical concern. Lion's mane contains compounds that may inhibit platelet aggregation. A 2013 in vitro study demonstrated that hot water extracts of Hericium erinaceus inhibited collagen-induced platelet aggregation in human platelet-rich plasma by up to 32% at high concentrations [5]. MOTS-c, through AMPK activation, could theoretically influence endothelial function and nitric oxide production, which also affects platelet behavior [1].

No case reports of bleeding events from this combination exist. The platelet effect of lion's mane is modest and dose-dependent, observed primarily at extract concentrations higher than standard oral supplementation achieves. Still, if you take anticoagulants (warfarin, apixaban, rivaroxaban) or antiplatelet agents (aspirin, clopidogrel), this theoretical additive effect on platelet function warrants discussion with your prescribing clinician.

Inflammatory Modulation: Additive, Not Dangerous

Both MOTS-c and lion's mane reduce pro-inflammatory cytokines. MOTS-c suppresses TNF-alpha and IL-6 through AMPK-mediated NF-kB inhibition [1]. Lion's mane polysaccharides reduced LPS-induced TNF-alpha production by 41% in a murine macrophage model [6]. An additive anti-inflammatory effect could be beneficial for users seeking metabolic and cognitive support. No evidence suggests that combined anti-inflammatory activity at supplement-grade doses produces clinically significant immunosuppression.

Dose-Separation Protocol

Even though a direct interaction is unlikely, separating the two compounds by 30 to 60 minutes is a reasonable practice. Here is why.

GI Tolerability

Lion's mane occasionally causes mild gastrointestinal discomfort, including bloating or loose stools, at doses above 1,000 mg daily [2]. MOTS-c is injected, so it does not directly irritate the gut. Taking lion's mane on a partially full stomach 30 to 60 minutes before or after an MOTS-c injection allows you to attribute any GI symptoms to the correct compound. This is practical troubleshooting, not a safety requirement.

Monitoring Windows

If you are already taking both, track these variables weekly for the first month:

• GI symptoms: bloating, nausea, stool changes. Rate each 0 to 3 daily.
• Bruising or bleeding: any new, unexplained bruising larger than a quarter. Note the location and size.
• Energy and cognition: simple self-rating scale. Both compounds aim to improve these outcomes, so deterioration may signal an adverse interaction.
• Fasting glucose (if you have a glucometer): MOTS-c's primary metabolic effect is on glucose regulation [1]. A drop below 70 mg/dL during combined use would warrant dose re-evaluation.

Who Should Be More Cautious

Most healthy adults experimenting with MOTS-c and lion's mane face minimal risk. Certain populations need to exercise more care.

People on Blood Thinners

The theoretical additive effect on platelet aggregation is most relevant here. Dr. Andrew Huberman's Stanford Lab podcast has popularized lion's mane supplementation, but the Endocrine Society's 2020 clinical practice guidelines on peptide therapies emphasize that "patients on anticoagulant therapy should disclose all supplements, including those perceived as low-risk, to their prescribing physician" [7]. If you take warfarin, monitor your INR more frequently during the first 4 weeks of adding lion's mane.

People with Autoimmune Conditions

Lion's mane stimulates immune function through beta-glucan activation of dendritic cells and macrophages [6]. MOTS-c modulates immune signaling through AMPK. If you have an autoimmune condition (lupus, rheumatoid arthritis, multiple sclerosis), the combined immune-modulating effects could theoretically aggravate flares. No published case reports confirm this, but the mechanism is plausible. Discuss the combination with your rheumatologist.

People with Hypoglycemia Risk

MOTS-c improves insulin sensitivity and glucose uptake. If you also take metformin, sulfonylureas, or insulin, adding MOTS-c already shifts your glucose lower. Lion's mane has shown modest blood glucose-lowering effects in diabetic rat models (fasting glucose reduced by 14.2% over 28 days at 200 mg/kg) [8]. Stacking two glucose-lowering interventions on top of diabetes medications increases hypoglycemia risk. Monitor fasting glucose daily during the first two weeks.

What the Evidence Actually Shows (and Does Not Show)

No human clinical trial has studied MOTS-c and lion's mane together. Zero. The safety profile of this combination is extrapolated entirely from the individual compound data and mechanistic reasoning.

MOTS-c Human Data Is Limited

As of May 2026, MOTS-c has been studied primarily in cell culture and murine models. The landmark 2015 paper by Lee et al. In Cell Metabolism established its metabolic effects in mice [1]. A 2021 observational study in Nature Communications found that endogenous MOTS-c levels correlate inversely with age and metabolic dysfunction in a cohort of 1,012 adults [9]. But exogenous MOTS-c injection in humans lacks Phase I safety data published in peer-reviewed journals.

Lion's Mane Has Stronger Clinical Evidence

The Mori et al. (2009) trial remains the most cited human study [2]. A 2019 randomized, double-blind, placebo-controlled trial of 77 overweight adults found that 3 capsules (500 mg each) of Hericium erinaceus daily for 8 weeks reduced depression and anxiety scores on the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) compared to placebo (p<0.05) [10]. A 2023 study in Nature published by researchers at the University of Queensland showed lion's mane extract enhanced neurite outgrowth and improved hippocampal memory in mice through activating the TrkB-ERK pathway [11].

The Gap You Are Filling with Self-Experimentation

When you combine MOTS-c with lion's mane, you are conducting an n=1 experiment with no published safety data on the specific combination. This is not unusual in the peptide and nootropic space. It does mean that systematic self-monitoring (as described above) is your primary safety tool.

Practical Protocol for Combined Use

Based on the available mechanistic and individual-compound data, here is a reasonable approach:

Step 1. Establish a baseline on each compound alone for at least 2 weeks before combining. Take lion's mane at your target dose (500 to 1,500 mg daily, standardized to at least 30% polysaccharides) for 14 days. Note GI tolerance, energy, sleep quality, and any bruising.

Step 2. Begin MOTS-c at the lower end of research dosing (5 mg subcutaneous, typically 3 to 5 times per week) while continuing lion's mane. Separate the oral lion's mane dose from the MOTS-c injection by at least 30 minutes.

Step 3. Monitor fasting glucose, GI symptoms, and bruising daily for the first 14 days of combined use. If fasting glucose drops below 70 mg/dL on two consecutive mornings, reduce the MOTS-c dose or frequency.

Step 4. At 30 days, obtain a basic metabolic panel and CBC with differential. Compare to your pre-combination baseline. Pay particular attention to platelet count and fasting glucose.

A 2022 review in Frontiers in Pharmacology of supplement-peptide interactions concluded that "the absence of shared metabolic pathways between injectable peptides and orally consumed fungal extracts substantially reduces the likelihood of clinically significant pharmacokinetic interactions" [12].